Cardiology

During AHA, investigators analyzed some of the differences in outcomes for men and women in hypertension drug trials.

Udenafil positively impacted measures of exercise performance in patients after Fontan, but did not improve peak VO2.

A new study from AHA 2019 has found patients receiving periprocedural colchicine did not decrease their risk of developing PCI-related injuries compared to patients receiving placebo.

A total of 61.4% of patients in the immediate angiography group and 64.0% of patients in the delayed group were alive 1 year post-cardiac arrest.

Results of the TWILIGHT-ACS study revealed use of ticagrelor plus aspirin following coronary intervention in patients with acute coronary syndrome increased the risk of major bleeding.

A national study underlined a persistent trend of cardiovascular events among US women near giving birth.

New findings from ESCaPE-MD show CD34+ cell therapy significantly benefitted patients with coronary microvascular dysfunction over 6 months.

A recent analysis of the FRANCE-TAVI registry presented at AHA 2019 has found self-expanding transcatheter heart valves were associated with an increased risk of all-cause mortality following TAVR.

One (1.4%) of 73 patients assigned to early surgery and 11 (15.3%) of 72 patients assigned to conventional treatment died from CV causes.

A new study from AHA 2019 has found that use of rivaroxaban rather than antiplatelet therapy after TAVR increased a patient's risk of death and bleeding events.

Investigators present data from the CREDENCE trial during AHA.

Taking a routine invasive approach had no impact on clinical outcomes or quality of life in patients with chronic kidney disease as well as stable ischemic heart disease.

Results of the ISCHEMIA trial were revealed at AHA 2019 and revealed little overall benefit of an invasive approach but saw improved angina control in patients with previous angina.

Apabetalone demonstrated tolerability and safety in the phase 3 BETonMACE trial but the study did not meet its primary end point of reduction in major adverse cardiovascular events (MACE).

The ORION-10 trial revealed 300 mg inclisiran twice-yearly reduced LDL-C levels by 58% in patients with atherosclerotic cardiovascular disease.

In a presentation during AHA, investigators present new evidence linking sleep issues with poorer outcomes for hypertension patients.

New empagliflozin data assesses the SGLT-2 inhibitor versus GLP-1 agonists and DPP-4 inhibitors for patients with heart failure.

Results of the COLCOT trial presented at AHA 2019 revealed colchicine use could reduce the risk of cardiovascular events by 35% in patients who recently suffered a myocardial infarction.

The adult heart failure study is the first of its kind: a completely decentralized, indication-seeking clinical trial.

Results from the 400,000-plus patient trial show a pulse detection app on the Apple Watch may aid users in detecting risks of atrial fibrillation.

George Mulligan, PhD, discusses during Kidney Week the results of a phase IIa study showing potential in a new drug to treat patients at risk for developing an acute kidney injury following cardiovascular surgery.

George Bakris, MD, discusses how nephrologists can work with other specialists and what the highlight of Kidney Week was.

George Bakris, MD, discusses the major study during Kidney Week, as well as what diseases should get more attention in future research.

Matthew Weir, MD talks about some of the challenges in nephrology and what has people buzzing while at Kidney Week.

Matthew Weir, MD, discusses the START-CKD trial at Kidney Week.